First Clinical Trial Launched by MDS Nordion to Study Innovative Cancer Treatment
26 Settembre 2006 - 3:00PM
PR Newswire (US)
New therapy provides hope for patients with secondary liver cancer
OTTAWA, Sept. 26 /PRNewswire-FirstCall/ -- MDS Nordion, a leading
provider of medical isotopes and radiopharmaceuticals, has received
approval from the U.S. Food and Drug Administration (FDA) to begin
the first clinical trial for a non-invasive, innovative cancer
therapy. This treatment called TheraSphere(R) has been developed
for patients with liver cancer. The clinical trial, expected to
begin in October, will enrol up to 150 patients with secondary
liver cancer from five existing TheraSphere(R) treatment centers in
the United States. TheraSphere(R) offers another option to the
limited number of treatments available for patients suffering from
secondary liver cancer. With this treatment, tiny radioactive glass
beads attack cancerous tumours in the liver, while minimizing the
impact on the patient's healthy tissues. Unlike chemotherapy, it
has few side effects. Patients rarely experience extreme fatigue,
nausea and vomiting usually associated with high-dose, systemic
chemotherapies. The treatment can generally be administered on an
outpatient basis as it does not usually require an overnight
hospital stay. "These clinical trials represent an excellent fit
with MDS Nordion's strategic direction and our commitment to
developing new, innovative technologies for people with cancer,"
said Steve West, President of MDS Nordion. "Secondary liver cancer
affects tens of thousands of patients every year in North America.
This clinical trial will evaluate the effectiveness and safety of
TheraSphere(R) with the goal of making this cancer therapy more
widely available to help more patients." "Over the last 5 years, I
have treated hundreds of patients by offering them an innovative
treatment with TheraSphere(R)," said Dr. Riad Salem, Interventional
Radiologist, Northwestern Memorial Hospital, Chicago. "The clinical
trial offers participating medical institutions the opportunity to
further their clinical experience and knowledge of this treatment.
We can build upon what is already known - TheraSphere(R) is a very
well-tolerated treatment option that often translates into a
positive experience for patients, families and institutions." About
TheraSphere(R) TheraSphere(R), Yttrium-90 glass microspheres, is a
low toxicity, out-patient liver cancer therapy which consists of
millions of small glass beads (20-30 micrometers in diameter). Each
bead has radioactive Yttrium-90 in it. The physician injects
TheraSphere(R) into the main artery of the patient's liver through
a small tube (catheter) and the tiny radioactive glass beads are
delivered directly into the liver tumour via blood vessels. The
radiation delivered destroys the tumour cells from within the
tumour, with minimal injury to surrounding health liver tissue. The
Yttrium-90 in TheraSphere(R) becomes Zirconium-90 as it loses
radioactivity. The radioactivity half-life of Yttrium-90 is 64.1
hours resulting in most of the radioactivity disappearing in
approximately 10-12 days following treatment with TheraSphere(R).
TheraSphere(R), 100% reimbursed by Medicare, is approved in the
U.S. as a Humanitarian Device for the treatment of hepatocellular
carcinoma (primary liver cancer). In collaboration with the U.S.
FDA, MDS Nordion also makes TheraSphere(R) available to patients
with limited treatment options for their secondary liver cancer.
For more information on TheraSphere(R), visit
http://www.therasphere.com/. About MDS Nordion MDS Nordion
(http://www.mds.nordion.com/) is a world leader in radioisotopes,
radiation and related technologies. MDS Inc. (TSX:MDS) (NYSE:MDZ)
has more than 8,800 highly skilled people in 28 countries. It
provides a diverse range of superior products and services to
increase customers' speed, precision and productivity in the drug
development and disease diagnosis processes. MDS is a global,
values-driven life sciences company, recognized for its reliability
and collaborative relationships that help create better outcomes in
the treatment of disease. Find out more at http://www.mdsinc.com/
or by calling 1-800-MDS-7222, 24 hours a day. DATASOURCE: MDS
Nordion CONTACT: Shelley Maclean, External Communications, MDS
Nordion, Tel: (613) 592-3400 ext. 2414, E-mail:
Copyright
Grafico Azioni Mds (NYSE:MDZ)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Mds (NYSE:MDZ)
Storico
Da Lug 2023 a Lug 2024
Notizie in Tempo Reale relative a Mds (Borsa di New York (NYSE)): 0 articoli recenti
Più Mds Articoli Notizie